RxDoctor Payments Data

Ruth Lim, MD

Internal Medicine · Huron, SDNPI 1215937297

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,475 of the $2,955 with a category attached, or 83.8%. AbbVie accounts for 87.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $2,475 and has fallen 94.8% since, to $129 in 2025. Among internal medicine clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,955in general payments, 2019–2025

Across 26 payments — averaging $113.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$141
  • Johnson & Johnson$36
  • Novo Nordisk$35
  • Boehringer Ingelheim$30
  • Lilly USA, LLC$28
  • plus $100 from 5 others

What the payments were for

  • Consulting fees$2,47584%
  • Food & beverage$48016%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,955 in reported general payments places this provider in the 90th percentile of 178 internal medicine providers in South Dakota.

See all internal medicine providers in South Dakota

Medicare billing

Part B allowed, 2024
$1,203
Medicare patients
25
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Combivent RespimatIpratropium/Albuterol Sulfate16$8,195
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,822
Omeprazole40$746
Albuterol Sulfate HfaAlbuterol Sulfate26$624
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen20$475
Buprenorphine Hcl13$371
Rosuvastatin Calcium16$347
Levothyroxine Sodium46$344
Gabapentin12$343
Simvastatin47$334
Ondansetron Hcl11$322
Lisinopril27$179
Fluticasone Propionate14$168
Cyclobenzaprine Hcl16$149
Tizanidine Hcl11$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimCombivent Respimat$30$8,19516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 178 internal medicine providers in South Dakota.

Other internal medicine in Huron

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →